Document is current
Any future updates will be listed below
-
Authors
Nakahara, Takeshi https://orcid.org/0000-0003-2811-8273
Noto, Shinichi https://orcid.org/0000-0002-6952-7770
Matsukawa, Miyuki https://orcid.org/0000-0003-2632-8808
Konishi, Yasuhito https://orcid.org/0000-0002-2171-8519
Toda, Rikiya https://orcid.org/0009-0003-4517-9163
Michikami, Daisaku
Murota, Hiroyuki https://orcid.org/0000-0002-0450-1377
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical
- License Information
-
More Information
Article History
Received: 21 July 2025
Accepted: 11 August 2025
First Online: 21 August 2025
Declarations
:
: Takeshi Nakahara has received consulting fees and/or speaker honoraria from Mitsubishi Tanabe Pharma, Taiho Pharmaceutical, Torii Pharmaceutical Co., Ltd, Maruho Co., Ltd, Sanofi, AbbVie, Eli Lilly Japan, Sun Pharma, and Otsuka Pharmaceutical Co., Ltd. Hiroyuki Murota has received consulting fees and/or speaker honoraria from Maruho Co., Ltd., Sanofi K.K., Pfizer Japan Inc., Torii Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., AbbVie GK, and Otsuka Pharmaceutical Co., Ltd. Shinichi Noto has received speaker honoraria from Otsuka Pharmaceutical Co., Ltd. Miyuki Matsukawa, Rikiya Toda, Yasuhito Konishi, and Daisaku Michikami are employees of Otsuka Pharmaceutical Co., Ltd.
: This study used secondary, anonymized data provided by DeSC. Therefore, no additional, individual-level informed consent was obtained for conducting this study. The study protocol was approved by the Ethics Committee of Otsuka Pharmaceutical Co., Ltd., Research and Development Division (Approval Number: 221013). The questionnaire for this survey was conducted by DeSC in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects in Japan and the Declaration of Helsinki.
